After taking montelukast i.e. montelukast sodium in patients with variant asthma, the efficacy can usually be seen within 1 day, but the efficacy of oral administration of this product in the treatment of acute asthma attack has not been determined, so it should not be used in the treatment of acute asthma attack.
Montelukast sodium belongs to the leukotriene modulator, has the effect of relieving airway inflammation, is conducive to reducing airway hyperresponsiveness, alleviate the symptoms of variant asthma, the drug’s average plasma half-life of 2.7-5.5 hours, generally in the taking of the drug 3 hours after the blood concentration will reach the peak, in the drug half-life, the effect will be more obvious, generally in the taking of the drug within 1 day of the therapeutic effect can occur.
Commonly used in the prevention and long-term treatment of asthma, but also for the treatment of allergic rhinitis.
Montelukast sodium may appear hallucinations, palpitations, dyspepsia, edema, bleeding, arthralgia and other adverse reactions after use, it is not recommended for patients who are allergic to the components of this product, and the efficacy of oral administration of this product for the treatment of acute asthma attacks has not been determined, so it should not be used for the treatment of acute asthma attacks.
Patients with atopic asthma are advised to visit a hospital in time and use the drug under the guidance of a physician.